$1.7 billion overnight, page-4

At a market cap circa $30m, I would contend (subject to success of phase 2 trials, nearing completion) that IMC is worth MORE than Tobira. And not just because our product has shown more efficacy or less side effects in preliminary NASH trials. But because IMC has a whole platform to develop more and more drugs, which means whoever buys IMC is going to acquire a whole pipeline of opportunities. Not to mention the many collaborations (c diff, infant autism, ASH, etc).

Then you add the products into the mix that are already out there on the OTC market getting sales (Protectyn, Travelan) it's hard not to get excited.

It's just a matter of time now before the market wakes up to this opportunity. It's been a long time coming but I feel we are now very close to a major inflection point.